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Abstract. Although several therapeutic options are available 
for hepatocellular carcinoma (HCC), the outcome is still very 
poor. One reason is the complexity of signal transduction in 
the pathogenesis of HCC. The aim of this study was to iden-
tify new HCC-related genes and to investigate the functions 
of these genes in the pathogenesis and progression of HCC. 
Whole genomes of 15 surgically resected HCC specimens 
were examined for copy number alterations with compara-
tive genomic hybridization. Gene expression was compared 
between HCC and normal liver tissues. The roles of the new 
genes in the progression of HCC were studied using cultured 
cell lines. Copy number gain in chromosome 8q was detected 
in 53% of HCC tissues examined. The gene that coded for 
collagen triple helix repeat containing 1 (CTHRC1), located 
at chromosome 8q22.3, was overexpressed in HCC compared 
with normal or liver cirrhosis tissues and identified as a new 
HCC-related gene. CTHRC1 deletion with short hairpin RNA 
significantly reduced proliferation, migration and invasion 
of HepG2 and Huh7 cells. In addition, mRNA of integrins 
β-2 and β-3 was downregulated, with deletion of CTHRC1 
in these cells. Immunohistochemical staining on resected 
HCC tissues showing positive staining areas for CTHRC1 
was significantly greater in poorly-differentiated HCC 
compared with well-differentiated HCC. Moreover, some 
cases showed strong staining for CTHRC1 in invasive areas 
of HCC. CTHRC1 has the potential to be a new biomarker 
for the aggressive HCC, and to be a new therapeutic target in 
treating HCC.
Introduction
Hepatocellular carcinoma (HCC) is the most common 
primary malignancy of the liver in adults. It is the 5th most 
frequent cancer worldwide and the 3rd leading cause of 
cancer mortality (1). Several approaches have been attempted 
for the treatment of HCC, such as surgical resection, trans-
arterial chemoembolization, radiofrequency ablation and 
orthotopic liver transplantation. More recently, an oral 
multikinase inhibitor, sorafenib, has become a key drug for 
non-resectable HCC (2). Sorafenib inhibits the serine/threo-
nine kinase activity of Raf-1 and B-Raf, the receptor tyrosine 
kinase activity of vascular endothelial growth factor recep-
tors (VEGFRs) 1, 2 and 3, and platelet-derived growth factor 
receptor β (PDGFR-β), the cellular signalings of which are 
implicated in the molecular pathogenesis of HCC.
Despite the variety of therapeutic options, and the many 
points of action of sorafenib, the prognosis of HCC is still very 
poor. Several factors account for the limited efficacy of these 
treatments. First, most patients have underlying liver disease 
[e.g., liver cirrhosis due to chronic hepatitis C virus (HCV) or 
hepatitis B virus (HBV) infection]. Second, HCC has a high 
rate of recurrence that is caused by intrahepatic metastasis or 
multicentric occurrence. Another reason for its poor outcome 
is that HCC is a complex and heterogeneous tumor, and many 
key signal transduction pathways and molecules other than 
those targeted by sorafenib are possibly implicated in the 
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pathogenesis of HCC. In addition, many genetic and epigenetic 
alterations such as copy number alteration (CNA), DNA meth-
ylation, or DNA mutation have been suggested as being related 
to the development of HCC (3,4). Therefore, it is important to 
have a clear landscape of the genomic aberrations in order to 
understand the multistep process of HCC progression.
Among the genetic alterations, CNAs can be found in almost 
all human malignancies. Several attempts have been made to 
identify CNAs by searching for new genes that are causative 
for HCC carcinogenesis. In fact, frequent copy number gains 
at chromosomes 1q, 8q and 20q, and frequent copy number 
losses at 1p, 4q, 8p, 16q and 17q have been identified in HCC 
using array-comparative genomic hybridization (CGH) (5-7). 
However, the roles of these CNAs in the pathogenesis of HCC 
have yet to be elucidated.
Given these facts, the purpose of the current study was to 
identify new HCC-related genes by investigating CNAs in the 
whole genome using array-CGH, and by focusing on specific 
genes included in the CNA region. Furthermore, by performing 
functional assays of the identified genes, we aimed to elucidate 
the role of the genes in the pathogenesis and progression of 
HCC, and to clarify whether the genes have the potential to be 
new therapeutic targets.
Materials and methods
Patients. Paired tumor and surrounding non-tumor liver 
tissues (liver cirrhosis) were collected from patients who 
underwent radical surgery for HCC at Mie University Hospital 
(Tsu, Japan). Normal liver tissues were obtained from trimmed 
scrap portions of donor livers used for living donor liver 
transplantation. In total, liver tissues were obtained from 15 
patients and 15 normal subjects. DNA copy number alterations 
(CNAs) were analyzed in HCC tissues, and gene expression 
was compared between HCC and normal tissues. Table I 
shows the patient characteristics. This study was approved 
by the Institutional Review Board of Mie University Hospital 
(authorization no. 285). Written informed consent was obtained 
from each patient included in the study. The study protocol 
conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the institution's 
human research committee.
Copy number analysis. GeneChip 50K single nucleotide 
polymorphism (SNP) mapping array analysis was performed 
according to the standard Single Primer GeneChip Mapping 
Assay protocol using a Human Mapping 50K Array Hind III 
(Affymetrix, Santa Clara, CA, USA). Individual SNP copy 
numbers and chromosomal regions with gains or deletions 
were evaluated with CNAG 2.0 (8).
Expression profiling. Oligonucleotide microarray experiments 
were carried out using Human Genome U133 Plus 2.0 arrays 
according to the manufacturer's instructions (Affymetrix). 
Data were analyzed with GeneSpring GX 7.3.1 (Silicon 
Genetics, Redwood City, CA, USA).
HCC cell lines. The human HCC cell lines HepG2 (RCB1648) 
and Huh7 (RCB1942) were purchased from the Riken Cell 
Bank (Tsukuba, Japan), Hep3B (ATCC HTB-52) and SK-Hep1 
(ATCC HB-8064) were purchased from the American Type 
Culture Collection (Manassas, VA), and HLE (JCRB0404) 
and PLC/PRF/5 (JCRB0406) were purchased from the Health 
Science Research Resources Bank (Osaka, Japan). All cell 
lines were cultured in Dulbecco's modified Eagle's medium 
(DMEM) (Life Technologies, Tokyo, Japan) supplemented 
with 1% penicillin/streptomycin (Life Technologies) and 
10% fetal calf serum (FCS) (Life Technologies) in a humidi-
fied atmosphere containing 5% CO2 at 37°C.
Qualitative reverse transcription polymerase chain reaction 
(PCR). The expression of CTHRC1 mRNA in the HCC cell 
lines was determined by reverse transcription PCR of total 
RNA. Total RNA was extracted from approximately 107 cells of 
each cell line with the RNeasy mini kit (Qiagen, Tokyo, Japan), 
and cDNA was synthesized by extension of oligo dT primers 
with PrimeScript reverse transcriptase (Takara Bio, Inc., Otsu, 
Japan). PCR of the cDNA was performed with Ex Taq 
(Takara Bio). The sense primer used for amplification of 
CTHRC1 was 5'-AGGGAGGTGGTGGACCTGTAT-3' and 
antisense primer was 5'-GCCAACCCAGATAGCAACAT-3'.
Quantitative real-time PCR. The cDNA of HCC tissues, 
non-tumorous tissues and HCC cell lines was synthesized from 
1 µg of total RNA and quantitative real-time PCR (qRT-PCR) 
was performed using the ABI prism 7300 Real-time PCR system 
(Applied Biosystems, Foster City, CA, USA) with EagleTaq 
master mix kits (Roche Molecular Systems, Branchburg, NJ, 
USA). The expression levels of target genes from triplicate reac-
tions were determined by normalization to β-actin according 
to the manufacturer's instructions. Primer sets are as follows: 
CTHRC1 forward, 5'-CCAAGGGGAAGCAAAAGG-3'; 
reverse, 5'-CCCTTGTAAGCACATTCCATTA-3'. Human 
integrin β-2 forward, 5'-CAGCAATGTGGTCCAACTCA-3'; 
reverse, 5'-GAGGGCGTTGTGATCCAG-3'. Human inte-
grin β-3 forward, 5'-CGCTAAATTTGAGGAAGAACG-3'; 
reverse, 5'-GAAGGTAGACGTGGCCTCTTT-3'.
Western blot analysis. Polyclonal antibody for CTHRC1 was 
generated by immunization of rabbits. HepG2 cells were 
fractionated using the ProteoExtract Subcellular Proteome 
Extraction Kit (Merck Millipore, Darmstadt, Germany) 
according to the manufacturer's instructions, and localiza-
Table I. Characteristics of HCC patients studied.
Gender Male 11
 Female 4
Age  62±8.7a
HBV serology Positive 7
 Negative 8
HCV serology Positive 8
 Negative 7
AFP (ng/ml)  885±3,107a
DCP (mAU/ml)  2,168±6,243a
aMean ± SD. HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, 
α-fetoprotein; DCP, des-γ-carboxy prothrombin.
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tion of CTHRC1 in HCC cells was determined by western 
blot analysis. Protein lysates of each fraction were sepa-
rated by SDS-polyacrylamide gel electrophoresis (12.5%) 
and transferred to polyvinylidene difluoride membranes. 
Blots were blocked with 5% milk in Tris-HCl (pH 7.5) with 
0.1% Tween-20 for 2 h and proved with primary antibody at 
4˚C overnight. The immunoblots were then probed with horse-
radish peroxidase-conjugated anti-rabbit secondary antibody 
(GE Healthcare, Amersham Place, UK) and visualized using 
ECL plus (GE Healthcare, Munich, Germany).
Knockdown of CTHRC1 mRNA. Three types of short hairpin 
RNA (ShRNA) against CTHRC1 and control ShRNA were 
constructed using the piGENE vector (Igene, Tokyo, Japan). 
Their target sequences are listed as follows: Sh1, GAAATGA 
ATTCAACAATTA; Sh2, AAGGAAGCCCTGAAATGAA; 
Sh3, AGGGAAAGCTTTGAGGAGT; and control (T7STOP), 
CACCTTTTTTTT. These ShRNAs and control plasmid were 
transfected into HepG2 cells and Huh7 cells with FuGENE HD 
(Roche, Mannheim, Germany), followed by the addition of 
1 µg/ml of puromycin after 24 h for selecting transfected cells. 
Cells were harvested 72 h later for analysis of gene expression, 
cell proliferation, migration and invasion.
Cell proliferation assay. Cell proliferation was assessed with 
the xCELLigence system (Roche Inc., Basel, Switzerland) 
according to the manufacturer's instructions. Briefly, each 
well of a 16-well microtiter plate (E-Plate 16) was filled with 
100 µl of DMEM to equilibrate the well membrane, and each 
plate was incubated for 30 min at 37˚C in 5% CO2. HCC cells 
transfected with ShRNA against CTHRC1 or control plasmid 
were suspended in 100 µl of DMEM and seeded at a density 
of 1x104 cells per well. Cells were cultured for 48 h with the 
Real-Time Cell Analyzer (RTCA) single plate (SP) instru-
ment placed in a standard incubator at 37˚C in 5% CO2. Then, 
cell proliferation was monitored by recording cell index (CI) 
values at 15-min intervals for 48 h.
Cell migration and invasion assays. Cell migratory and inva-
sive abilities were also assessed by the xCELLigence system. 
Briefly, cell migration was assessed by seeding HCC cells 
at 2x104/well on a fibronectin-coated CIM-16 plate, and cell 
invasion was assessed by seeding HCC cells at 3x104/well 
on a CIM-16 plate coated with Matrigel (Becton-Dickinson, 
Tokyo, Japan). Both cell invasion and migration were moni-
tored by recording the CI at 15-min intervals for 48 h.
Real-time PCR array. The changes in gene expression related 
to cell migration and invasion by CTHRC1 knockdown 
in HCC cells were analyzed with the Human Extracellular 
Matrix and Adhesion Molecules RT2 Profiler PCR Array 
(SABiosciences, Frederick, MD, USA) according to the 
manufacturer's instructions. These changes were confirmed 
also by qRT-PCR.
Immunohistochemistry. Immunohistochemical staining 
for CTHRC1 was performed on surgically resected HCC 
tissues using the Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA, USA). Deparaffinized sections were heated 
for 5 min in citrate buffer at 100˚C with a pressure cooker to 
reactivate the antigen, and treated with 0.3% H2O2 in meth-
anol for 30 min to abolish endogenous peroxidase activity. 
Sections were blocked with 1% goat serum in phosphate-buff-
ered saline, covered with primary antibody at 4˚C overnight, 
and then covered with second-step biotinylated antibody for 
30 min, and incubated with peroxidase-labeled streptavidin 
for 30 min. After washing, sections were incubated with 
0.05% diaminobenzidine/0.15% H2O2 and counterstained 
with 10% hematoxylin (Wako Pure Chemical Industries, Ltd., 
Osaka, Japan).
Statistical analysis. Comparisons of gene expression, cell 
proliferation, migration and invasion were performed using 
the two-tailed Student's t-test. For differences between rates, 
Fisher's exact test was used. p<0.05 was considered statisti-
cally significant.
Results
CTHRC1 was identified as a new HCC-related gene. The 
chromosomes which had frequent CNAs (≥20%) in 15 HCC 
tissues are listed in Table II. Among them, we focused on 8q, 
in which CNAs were detected in 53% of HCC tissues, because 
CNAs in 8q have been also reported very frequently by several 
groups (9-11), but have not been studied in detail. Through 
gene expression profiling of 8q, we identified CTHRC1 
located at 8q22.3 as a new HCC-related gene, of which the 
expression level was higher in HCC compared with normal 
tissues by 13.5-fold (Fig. 1A). Moreover, re-validation with 
qRT-PCR revealed that expression levels of CTHRC1 mRNA 
increased from normal tissues to liver cirrhosis and HCC in a 
stepwise manner (Fig. 1B). We investigated the expression of 
CTHRC1 mRNA in HCC cell lines by RT-PCR. As shown in 
Fig. 1C, CTHRC1 transcripts were detected in all 6 HCC cell 
lines. Localization of the CTHRC1 protein in HCC cells was 
also investigated using HepG2. HepG2 cells were fraction-
ated and each fraction was analyzed for CTHRC1 expression 
by western blot analysis. Fig. 1D shows that the 26-kDa 
CTHRC1 protein was expressed in membrane fractions of the 
HepG2 cells.
CTHRC1 promotes proliferation of HCC cells. As it has been 
reported that CTHRC1 is involved in tissue remodeling in 
Table II. Chromosomes which had frequent copy number 
alterations in HCC.
 Gain Loss
 --------------------------------------------------------------- ---------------------------------------------------------------
Chromosome Frequency (%) Chromosome Frequency (%)
  1q 60 17p 47
  8q 53   8p 27
13q 27 16q 27
20q 27   1p 20
  6p 27   2q 20
17q 20 13q 20
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rheumatoid arthritis and injured arteries by promoting the 
migration of fibroblasts (12), we hypothesized that CTHRC1 
might have some role in the proliferation and motility of HCC 
cells. First, we investigated the effect of CTHRC1 on the 
proliferation of HCC cells. Three types of ShRNA were used 
to suppress the expression of CTHRC1 in HepG2 and Huh7 
cells. The knockdown efficiency was confirmed by qRT-PCR 
(Fig. 2A and B). As shown in Fig. 2C and D, cell proliferation 
after 24 and 48 h assessed with xCELLignece system was 
Figure 1. Results of expression analyses. (A) Gene expression profiling of 
chromosome 8q. CTHRC1 located at 8q22.3 of which expression level was 
13.5-fold higher in HCC compared with normal liver tissues was identified 
as a new HCC-related gene. (B) Expression levels of CTHRC1 mRNA in 
each tissue. The expression levels of CTHRC1 mRNA increased from 
normal tissues to liver cirrhosis and HCC in a stepwise manner (*p<0.05). 
(C) Expression of CTHRC1 mRNA in HCC cell lines. (D) Expression of 
CTHRC1 in each cell fraction assessed by western blot analysis. A 26-kDa 
CTHRC1 protein was detected in membrane fractions.
Figure 2. Functional analyses following CTHRC1-deletion in HCC cells. 
Inhibition of CTHRC1 mRNA in (A) HepG2 and (B) Huh7 with short hairpin 
(ShRNA). Cell proliferation of (C) HepG2 and (D) Huh7. Cell proliferation 
after 24 and 48 h was significantly decreased in both the HepG2 and Huh7 cells 
with CTHRC1 knockdown compared with the control cells. (E) Cell migration 
of Huh7. Cell invasion of (F) HepG2 and (G) Huh7. Both cell migration and 
invasion were significantly reduced by CTHRC1 knockdown. The data are 
expressed as the mean ± SD relative to control of five independent experiments 
(*p<0.05, **p<0.01).
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significantly decreased in both the HepG2 and Huh7 cells with 
CTHRC1 knockdown compared with the control cells.
CTHRC1 promotes migration and invasion of HCC cells. 
We next examined the influence of CTHRC1 knockdown on 
HCC cell migratory activity. As shown in Fig. 2E, CTHRC1 
knockdown caused a significant reduction in cell migration 
after 24 h in the Huh7 cells compared with the control cells. 
In addition, the results of the cell invasion assay using the 
Matrigel-coated plate showed that the cell invasions of both 
the HepG2 and Huh7 cells after 24 h were also significantly 
reduced in the CTHRC1-depleted cells compared with the 
control cells (Fig. 2F and G).
CTHRC1 knockdown reduces integrin β mRNA in HCC cells. 
To elucidate the mechanism of the suppression of cell migratory 
and invasive activity in HCC cells by CTHRC1 knockdown, we 
compared the mRNA expression, which related to cell migra-
tion and invasion between the CTHRC1-depleted HepG2 cells 
and the control cells, using real-time PCR array. The results 
suggested that the expression of integrin β was affected by 
suppression of CTHRC1 mRNA (data not shown). To confirm 
these results, we next performed qRT-PCR to examine the 
changes in the expression levels of integrin β mRNA in HCC 
cells after knockdown of CTHRC1. As shown in Fig. 3, mRNA 
expressions of integrin β-2 and integrin β-3 were significantly 
reduced with CTHRC1 depletion in both the HepG2 and Huh7 
cells. On the other hand, no cell proliferation, migration/inva-
sion, or amount of integrin β mRNA in HCC changed with 
overexpression of CTHRC1 (data not shown).
CTHRC1 is expressed in the invasive area of HCC tissues. 
Forty-one surgically resected HCC specimens and adjacent 
non-tumor tissues were examined for CTHRC1 expression 
by immunohistochemistry. The HCC tissues were divided 
into three groups according to their degree of differentiation: 
well-differentiated HCC, moderately-differentiated HCC and 
poorly-differentiated HCC. The levels of CTHRC1 expression 
were analyzed in each group and the percentages of positive 
staining area were divided into three categories. The results 
are summarized in Table III. The rate for the positive area 
for CTHRC1 greater than 66% was significantly higher in 
poorly-differentiated HCC than that of well-differentiated 
HCC (71.4 vs. 18.2%, p<0.05). The differences of these rates 
in both between well-differentiated HCC and moderately-
differentiated HCC, and between moderately-differentiated 
HCC and poorly-differentiated HCC were not significant, 
probably due to the small sample number. None of the patients 
had positive CTHRC1 staining in the adjacent non-tumorous 
areas. Interestingly, some patients showed strong positive 
staining for CTHRC1 in the HCC cells close to fibrous bound-
aries (Fig. 4) and in invasive areas (Fig. 4B, arrowheads), 
suggesting high migratory and invasive activity of these 
cells.
Discussion
Despite the availability of several therapeutic options, it is 
still difficult to control the progression of HCC completely. 
One reason is the complexity of signal transduction in HCC; 
in other words, a large number of molecules are involved in 
the pathogenesis of HCC. Therefore, it is important to search 
for the novel molecules related to HCC progression in order to 
understand the mechanism of its pathogenesis and to achieve 
better prognosis. In this study, we identified CTHRC1 located 
at chromosome 8q22.3 as a novel HCC-related gene. The 
results of functional assay showed that CTHRC1-deletion 
caused reduced cell proliferation and motility in HCC cells. 
Figure 3. Expression of integrin mRNA following CTHRC1-deletion in HCC 
cells. (A) Expression of integrin β-2 in HepG2 and (B) Huh7. Expression level 
of integrin β-2 mRNA was significantly decreased with CTHRC1-depletion 
in HCC cells. (C) Expression of integrin β-3 in HepG2 and (D) Huh7. 
Expression level of integrin β-3 mRNA was also significantly decreased with 
CTHRC1-depletion in HCC cells. The data are expressed as the mean ± SD 
relative to control of five independent experiments (**p<0.01).
Table III. Summary of immunohistochemical staining.
 Extent of staining area
 -------------------------------------------------------------------------
 Case 0-33% 34-66% 67-100%
Total HCC 41 36.6 24.4 39.0
Well diff 11 63.6 18.2 18.2
Mod diff 23 26.1 34.8 39.1
Poorly diff   7 28.6 0   71.4a
Well diff, well-differentiated HCC; mod diff, moderately-differentiated 
HCC; poorly diff, poorly-differentiated HCC. ap<0.05 vs. well diff.
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In addition, integrin β mRNA expression was decreased by 
knockdown of CTHRC1 in HCC cells. Moreover, the CTHRC1 
protein was overexpressed in HCC tissues, especially in 
poorly-differentiated HCCs.
We first analyzed the whole genome for CNA using 
array-CGH and found copy number gain of 8q in 53% of the 
HCC tissues. We next performed gene expression analysis of 
8q and identified CTHRC1 as a novel HCC-related gene. Our 
results showed that CTHRC1 was overexpressed in HCC 
tissues compared with the surrounding non-tumor tissues. 
Furthermore, CTHRC1 mRNA was upregulated in all HCC 
cell lines examined, and the CTHRC1 protein was located 
in the cell membranes of the HCC cells. The mammalian 
CTHRC1 gene was first identified in balloon-injured arteries 
by Pyagay et al (12). This gene is highly conserved among 
vertebrates. The CTHRC1 protein contains an NH2-terminal 
peptide for extracellular secretion, a short collagen triple 
helix repeat of 36 amino acids, and a COOH-terminal 
globular domain. Although CTHRC1 expression was not 
detectable in normal arteries, on injury, it was transiently 
expressed by fibroblasts of the remodeling adventitia and 
by smooth muscle cells of the neointima. Durmus et al (13) 
reported that CTHRC1 was highly expressed in developing 
bones and cartilage, the bone matrix and periosteum of 
adult bones, and in the epithelium-mesenchymal interface 
including epidermis, airway epithelium, and esophageal 
epithelium. In addition, these sites of CTHRC1 expression 
were found to overlap considerably with those reported for 
the transforming growth factor β (TGF-β) family members 
and interstitial collagens (13). Kimura et al also reported 
that CTHRC1 increased bone mass as a positive regulator 
of postnatal bone formation (14). These investigators found 
that CTHRC1-null mice had a decreased number of osteo-
blasts and low bone mass, while CTHRC1 transgenic mice 
had an increased number of osteoblasts and displayed high 
bone mass. Furthermore, expression of CTHRC1 has been 
reported in stromal cells of breast cancer (15). Using cDNA 
arrays, Tang et al suggested that the CTHRC1 gene was 
aberrantly expressed in several types of human solid cancer 
cells, especially in cancers of the gastrointestinal tract, lung, 
breast, thyroid, ovarian, cervix, liver and pancreas (16). 
The results of the present study were congruent with the 
report by Tang et al (16). Although it is still unclear whether 
CTHRC1 has any function in carcinogenesis, several reports 
have suggested that inflammation and tissue repair are tightly 
linked with the development of cancer (17,18). Therefore, it 
is possible that CTHRC1 plays a certain role in the early 
stage of carcinogenesis of several cancers, including HCC.
To further elucidate the potential roles of CTHRC1 in HCC 
progression, we next analyzed the effect of CTHRC1 deletion 
on the proliferation, migration and invasion of HCC cells. Our 
results showed that HCC cell proliferation was reduced by 
the deletion of CTHRC1. Moreover, knockdown of CTHRC1 
also reduced the migratory and invasive ability of HCC cells. 
Several previous studies have suggested that CTHRC1 is 
related to the motility and invasion of both non-tumor and 
tumor cells. Using a microarray, Turashvili et al found that the 
CTHRC1 gene was upregulated in invasive lobular breast carci-
noma, suggesting the relation of CTHRC1 to carcinogenesis 
and cancer progression (19). Using the scratch wound healing 
assay, Pyagay et al showed that both PAC1 cells and embry-
onic fibroblasts overexpressing CTHRC1 increased migratory 
activities compared with control cells (12). Tang et al reported 
that CTHRC1 expression was significantly higher in invasive 
melanoma than in non-invasive melanoma (16). In addition, the 
experimental results of Tang et al with the Boyden chamber 
also showed that when CTHRC1 expression was inhibited 
with small interfering RNA (siRNA), migration of melanoma 
cells was significantly reduced (16). Our experimental results 
with the real-time cell analyzer indicated that CTHRC1 plays 
important roles, not only in proliferation or migration, but also 
in invasion of HCC cells, supporting the findings of previous 
reports. Therefore, there is a possibility that CTHRC1 is a new 
target for therapy of HCC especially for preventing metastasis.
Next, to elucidate the mechanism of how CTHRC1 affects 
the motility of HCC cells, we analyzed the changes in mRNA 
expression. The results of the mRNA array suggested that 
expression of integrin β-2 and β-3 mRNA was reduced 
by CTHRC1 deletion; this was confirmed by qRT-PCR. 
Integrins are a superfamily of transmembrane receptors 
that form heterodimers of α- and β-subunits. By binding to 
extracellular matrix (ECM) components, integrins mediate 
Figure 4. Immunohistochemistry for CTHRC1 on HCC tissues. (A and B) Strong positive staining for CTHRC1 was observed in the HCC cells close to 
fibrous boundaries, while non-tumor parts were negative for CTHRC1. (B, arrowheads) HCC cells invading surrounding normal liver tissues were strongly 
positive for CTHRC1. T, tumor; NT, non-tumor. Original magnification, x200.
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cell adhesion and direct a number of cellular processes 
such as proliferation, migration and differentiation (20-22). 
Integrins are also important in promoting cell survival 
by preventing anoikis, which is apoptosis induced by 
anchorage-dependent cells detaching from the surrounding 
ECM (23,24). There has been accumulating evidence 
showing that integrins β-2 and β-3 have a relationship with 
cancer progression and migration, including HCC (25-31). 
For example, Li et al reported that the downregulation of 
integrin β-3 in small cell lung cancer cells reduced cell 
migration/invasion and induced apoptosis (30). Our results 
suggest that CTHRC1 promotes the migration/invasion 
of HCC cells, and also increases cell survival of HCC 
by inhibiting anoikis via integrin β expression. However, 
no cell proliferation, migration/invasion, or amount of 
integrin β mRNA in HCC changed with overexpression 
of CTHRC1 (data not shown). Presumably, the expression 
level of CTHRC1 in HCC cells is already sufficient; there-
fore, increasing its expression does not affect these cell 
processes to any greater degree. In addition, the detailed 
mechanism on how CTHRC1 regulates the expression of 
integrin β remains to be elucidated.
Another possible mechanism by which CTHRC1 mediates 
cell motility is activation of Wnt signaling. Yamamoto et al 
found that CTHRC1 is a Wnt cofactor protein that selectively 
activates the planar cell polarity (PCP) pathway by stabilizing 
ligand-receptor interaction (32). The PCP pathway of Wnt 
signaling is mediated by the activation of small GTP-binding 
proteins, including Rac, Rho, Jun N-terminal kinase and 
Rho-associated kinase, and regulates actin polymerization and 
cell migration (33,34). Therefore, it is possible that CTHRC1 
promotes cell migration through activation of the PCP pathway 
of Wnt signaling.
Finally, our results of immunohistochemical staining 
for CTHRC1 showed that poorly-differentiated HCC had a 
higher expression level of CTHRC1 compared with well-
differentiated HCC, supporting previous findings in invasive 
breast cancer (19). Moreover, strongly positive staining was 
observed in tumor cells around the cancer borderlines or 
invasive areas in several cases, suggesting that those cells 
had a higher activity level of proliferation and migration. 
These results indicate that CTHRC1 can be a new biomarker 
for aggressive HCC.
During preparation of this manuscript, Park et al reported 
the roles of CTHRC1 in pancreas cancer (35) and very recently, 
Chen et al also reported CTHRC1 expression in HCC (36). 
They found CTHRC1 increased motility and adhesiveness of 
pancreas cancer cells and HCC cells. Moreover, Chen et al 
also reported HCC with higher CTHRC1 mRNA expression 
had worse prognosis (36). Our results are clearly supporting 
these findings. In addition, our data add the information that 
CTHRC1 protein is actually expressed in human HCC tissues, 
more prominently in cancer cells which are supposed to be 
aggressive.
Taken together, the results of the present study obtained 
from cultured cell lines and human HCC tissues indicated that 
CTHRC1 is upregulated in HCC cells and promotes cell prolif-
eration, migration and invasion. CTHRC1 has the potential to 
be a new biomarker for types of HCC with poor prognosis, and 
to be a new therapeutic target for HCC.
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